CLSP-5282, a first-in-class T cell engager targeting KRasG12V mutant peptide presented on HLA-A*03:01

Written By Julie DeSander

GO BACK TO PRESS RELEASES & MEDIA

Presentation

April 20, 2026

CLSP-5282, a first-in-class T cell engager targeting KRas G12V mutant peptide presented on HLA-A*03:01

Julie DeSander
Previous

Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026
Next

GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025.